Many genetic therapies require efficient delivery to immune cells, but conventional lipid nanoparticles (LNPs) primarily accumulate in the liver, limiting their effectiveness for immune-focused applications. Cytofinity™-SP is a PEG-free LNP formulation engineered to detarget the liver while achieving high spleen tropism and enhanced delivery to immune cells. By enabling more targeted delivery to the immune system, Cytofinity™-SP is designed to support next-generation therapeutic approaches, including in vivo CAR, in vivo gene editing, and immunotherapy.
Target Tissues:
- Spleen
Potential Applications:
- In Vivo CAR
- In Vivo Gene Editing
- Immunotherapy
Supporting Data:
1. Cytofinity-SP LNPs can be tuned to target the spleen
Luc-mRNA-loaded Cytofinity LNPs (Cytofinity-SP) exhibited predominate spleen tropism